|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
Press Release of Chembio Diagnostics, Inc., dated May 5, 2022
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Chembio Diagnostics, Inc.
|
||
Dated: May 5, 2022
|
By:
|
/s/ Richard L. Eberly
|
Chief Executive Officer and President
|
• |
Achieved total revenue of $18.8 million including record quarterly product revenue of $18.5 million in the first quarter of 2022, representing growth of 116% and 360%, respectively, compared to the prior year period:
|
o |
U.S. product revenue of $4.5 million, representing growth of 530% compared to the prior year period
|
o |
Latin America product revenue of $12.5 million, compared to $0.3 million in the prior year period
|
• |
Completed shipments under the $28.3 million purchase order from Bio-Manguinhos for DPP SARS-COV-2 Antigen Tests in Brazil and continued shipments on the $4 million HIV test purchase order supported by The Global Fund, which are expected
to be completed in the second quarter of 2022
|
• |
Improved gross product margin to 18% in the first quarter of 2022 from negative 9% in the fourth quarter of 2021
|
• |
Reduced cash usage in the first quarter of 2022 to $4.4 million, from $8.7 million in the prior year period and $7.2 million in the preceding quarter
|
• |
Expanded distributor relationships in Europe to supply the Sure Check HIV Self-tests in the UK and France
|
• |
Enhanced operations at Chembio Diagnostics Brazil by increasing low-cost manufacturing capabilities for over-the-counter packaging to support Sure Check Self-test supply for state, local and retail pharmacies
|
|
• |
Focus on higher margin business in growth markets
|
• |
Lower manufacturing costs
|
• |
Reduce infrastructure costs
|
• |
Strategic review of non-core businesses and assets:
|
• |
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by,
for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.
|
|
• |
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the
suppliers of those products.
|
|
|
For the three months ended
(Unaudited)
|
||||||||
March 31, 2022
|
March 31, 2021
|
|||||||
REVENUES:
|
||||||||
Product revenue
|
$
|
18,527,456
|
$
|
4,024,662
|
||||
R&D revenue
|
18,173
|
1,106,639
|
||||||
Government grant income
|
-
|
3,350,000
|
||||||
License and royalty revenue
|
270,982
|
243,058
|
||||||
TOTAL REVENUES
|
18,816,611
|
8,724,359
|
||||||
COSTS AND EXPENSES:
|
||||||||
Cost of product revenue
|
15,223,861
|
3,548,441
|
||||||
Research and development expenses
|
1,653,706
|
2,863,338
|
||||||
Selling, general and administrative expenses
|
6,946,271
|
6,085,067
|
||||||
Impairment, restructuring, severance and related costs
|
3,043,179
|
83,087
|
||||||
TOTAL COSTS AND EXPENSES
|
26,867,017
|
12,579,933
|
||||||
LOSS FROM OPERATIONS
|
(8,050,406
|
)
|
(3,855,574
|
)
|
||||
OTHER EXPENSE:
|
||||||||
Interest expense, net
|
(733,561
|
)
|
(712,477
|
)
|
||||
LOSS BEFORE INCOME TAXES
|
(8,783,967
|
)
|
(4,568,051
|
)
|
||||
Income tax (expense)/benefit
|
(6,327
|
)
|
67,888
|
|||||
NET LOSS
|
$
|
(8,790,294
|
)
|
$
|
(4,500,163
|
)
|
||
Basic and diluted loss per share
|
$
|
(0.29
|
)
|
$
|
(0.22
|
)
|
||
Weighted average number of shares outstanding, basic and diluted
|
30,090,045
|
20,163,386
|
|
March 31, 2022
|
December 31, 2021
|
|||||||
- ASSETS -
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
24,399,388
|
$
|
28,772,892
|
||||
Accounts receivable
|
9,879,954
|
11,441,107
|
||||||
Inventories, net
|
11,844,121
|
12,920,451
|
||||||
Prepaid expenses and other current assets
|
2,097,491
|
2,096,399
|
||||||
TOTAL CURRENT ASSETS
|
48,220,954
|
55,230,849
|
||||||
FIXED ASSETS:
|
||||||||
Property, plant and equipment, net
|
8,414,313
|
8,556,773
|
||||||
Finance lease right-of-use asset, net
|
190,526
|
191,870
|
||||||
TOTAL FIXED ASSETS, net
|
8,604,839
|
8,748,643
|
||||||
OTHER ASSETS:
|
||||||||
Operating lease right-of-use assets, net
|
5,693,482
|
5,891,906
|
||||||
Goodwill
|
-
|
3,022,787
|
||||||
Deposits and other assets
|
370,940
|
358,010
|
||||||
TOTAL ASSETS
|
$
|
62,890,215
|
$
|
73,252,195
|
||||
- LIABILITIES AND STOCKHOLDERS’ EQUITY -
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
10,542,851
|
$
|
13,127,993
|
||||
Current portion of long-term debt
|
2,100,000
|
1,200,000
|
||||||
Operating lease liabilities
|
916,524
|
886,294
|
||||||
Finance lease liabilities
|
72,203
|
68,176
|
||||||
TOTAL CURRENT LIABILITIES
|
13,631,578
|
15,282,463
|
||||||
OTHER LIABILITIES:
|
||||||||
Long-term operating lease liabilities
|
5,733,214
|
5,976,151
|
||||||
Long-term finance lease liabilities
|
134,955
|
139,678
|
||||||
Long-term debt, less current portion, net
|
16,855,322
|
17,589,003
|
||||||
TOTAL LIABILITIES
|
36,355,069
|
38,987,295
|
||||||
STOCKHOLDERS’ EQUITY:
|
||||||||
Common stock - $0.01 par value
|
302,699
|
301,050
|
||||||
Additional paid-in capital
|
166,483,376
|
165,772,636
|
||||||
Accumulated deficit
|
(139,800,154
|
)
|
(131,009,860
|
)
|
||||
Treasury stock
|
(206,554
|
)
|
(206,554
|
)
|
||||
Accumulated other comprehensive (loss)
|
(244,221
|
)
|
(592,372
|
)
|
||||
TOTAL STOCKHOLDERS’ EQUITY
|
26,535,146
|
34,264,900
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
62,890,215
|
$
|
73,252,195
|
|
March 31, 2022
|
March 31, 2021
|
|||||||
Net cash used in operating activities
|
$
|
(4,368,959
|
)
|
$
|
(7,261,260
|
)
|
||
Net cash used in investing activities
|
(286,544
|
)
|
(1,239,168
|
)
|
||||
Net cash used by financing activities
|
(55,444
|
)
|
(129,341
|
)
|
||||
Effect of exchange rate changes on cash
|
337,442
|
(85,579
|
)
|
|||||
INCREASE IN CASH AND CASH EQUIVALENTS
|
(4,373,504
|
)
|
(8,715,348
|
)
|
||||
Cash and cash equivalents - beginning of the period
|
28,772,892
|
23,066,301
|
||||||
Cash and cash equivalents - end of the period
|
$
|
24,399,388
|
$
|
14,350,953
|